Last A$0.02 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 1:41 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Open
A$0.02
Previous Close
A$0.02
Day High
A$0.02
Day Low
A$0.02
52 Week High
10/30/13 - A$0.03
52 Week Low
09/18/13 - A$0.0050
Market Cap
16.1M
Average Volume 10 Days
1.4M
EPS TTM
A$-0.0045
Shares Outstanding
946.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMUGENE LTD (IMU)

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited, a pharmaceutical company, is engaged in the research, development, and commercialization of health technologies in Australia. The company’s drug delivery platform technology, Linguet enables the active ingredient of drugs to be absorbed into the bloodstream when placed inside the cheek or under the tongue for the treatment of Vitamin D deficiency, Parkinson’s disease, osteoporosis, and non-steroidal anti-inflammatory drugs. The company is also involved in the development of Vitamin D tablet for buccal delivery; and lead cancer vaccine product targeting gastric cancer and breast cancer. Imugene Limited is based in Armadale, Australia.

imugene ltd (IMU) Top Compensated Officers

Executive Director and Member of Audit Commit...
Total Annual Compensation: A$63.9K
Joint Company Secretary
Total Annual Compensation: A$72.8K
Company Secretary
Total Annual Compensation: A$12.0K
Compensation as of Fiscal Year 2013.

imugene ltd (IMU) Key Developments

Mymetics Corporation and Imugene Partner to Develop Cancer Immunotherapy Vaccine Candidate

Mymetics Corporation has entered into an exclusive agreement with Imugene to manufacture and develop its cancer immunotherapy, HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015. Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.

Mymetics Signs an Exclusive Agreement with Imugene to Manufacture and Develop its Cancer Immunotherapy HER-Vaxx

Mymetics announced that it has signed an exclusive agreement with Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015. Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.

Imugene Limited Appoints Otto Buttula as a Non-Executive Director

Imugene Limited has appointed small caps research analyst and investor Mr. Otto Buttula as a Non-Executive Director of Imugene. Mr. Buttula is the second larger shareholder in Imugene, following Executive Chairman, Mr. Paul Hopper. Mr. Buttula has experience in research, technology and financial services positions over the past 25 years, having held directorships in a number of public companies. Buttula's experience includes co-founding and CEO and Managing Director of IWL Limited. Buttula also founded and was Managing Director for Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited. More recently, he was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited, now HUB24 Limited.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMU:AU A$0.02 AUD 0.00

IMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMU.
View Industry Companies
 

Industry Analysis

IMU

Industry Average

Valuation IMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 505.2x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 864.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMUGENE LTD, please visit www.imugene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.